Latest NovoCure Stories

2014-09-25 08:26:59

Analyses of PRiDe, a registry of 457 recurrent glioblastoma patients, show that patients treated with the NovoTTF(TM)-100A System at their first and second recurrences had median overall survivals of 20.0 and 8.5 months, respectively ST. HELIER, Jersey, Sept. 25, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that survival and efficacy data from its U.S. patient registry will be presented at the European Society for Medical Oncology (ESMO) Meeting...

2014-05-08 12:29:01

#TuneIn2GBM Social Media Campaign to Raise Awareness to Help Fight a Deadly Form of Brain Cancer PORTSMOUTH, N.H., May 8, 2014 /PRNewswire/ -- For the second consecutive year, Novocure is sponsoring its Tune-In to GBM campaign, a public call to action to "Tune-In" to glioblastoma (GBM) during National Brain Cancer Awareness Month this May. After the success of last year's inaugural campaign, Novocure is excited to combine forces with the Cancer Support Community, the Chris Elliott...

2011-04-16 00:44:03

First ever medical device therapy indicated as an alternative to chemotherapy for cancer Novocure today announced that the U.S. Food and Drug Administration (FDA) approved the NovoTTF-100A System (NovoTTF) for the treatment of adult patients with glioblastoma multiforme (GBM) brain tumors, following tumor recurrence after receiving chemotherapy. The portable, wearable device delivers an anti-mitotic, anti-cancer therapy as patients maintain their normal daily activities. The NovoTTF is a...

2011-03-17 18:24:00

WASHINGTON, March 17, 2011 /PRNewswire/ -- Novocure announced today that the U.S. Food and Drug Administration (FDA) Neurological Devices Advisory Panel of the Medical Devices Advisory Committee voted (7 yes; 3 no; 2 abstain) that for patients with supra-tentorial glioblastoma multiforme (GBM) tumors that recur after maximal surgical and radiation treatments, there is reasonable assurance that the benefits of the NovoTTF-100A System (NovoTTF) outweigh its risks when administered as a...

2010-11-19 12:00:00

MONTREAL, Nov. 19, 2010 /PRNewswire/ -- Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy. Professor Zvi Ram, chairman of the Department of Neurosurgery at Tel-Aviv Sourasky Medical Center, presented the data at the Society for Neuro-Oncology (SNO) Annual...

2010-10-11 14:04:33

Data presented today at the 35th European Society for Medical Oncology Congress Novocure reported today that patients with advanced non-small cell lung cancer (NSCLC) achieved a significant increase in survival time when tumor treating fields (TTF) therapy was added to chemotherapy, as compared to previously reported outcomes for patients receiving chemotherapy alone. Dr. Miklos Pless, head of medical oncology at the Winterthur Hospital Cancer center in Switzerland, presented the data at the...

Word of the Day
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).